Organogenesis Holdings (ORGO) EBIT Margin (2017 - 2026)

Organogenesis Holdings' EBIT Margin history runs 10 years deep, the most recent figure standing at 185.05% for Q1 2026.

• In Q1 2026, EBIT Margin fell 15420.0% year-over-year to 185.05%; the TTM figure through Mar 2026 stood at 6.27% (down 100.0% YoY), while the FY2025 annual figure was 1.75%, up 201.0% from the prior year.
• EBIT Margin was 185.05% for Q1 2026 at Organogenesis Holdings, down from 12.61% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 13.74% in Q3 2025 to a low of 185.05% in Q1 2026.
• Historically, EBIT Margin has averaged 10.19% across 5 years, with a median of 1.52% in 2022.
• The sharpest annual moves came in 2024 and 2026: EBIT Margin jumped 934 bps in 2024, then sank 15420 bps in 2026.
• A 5-year view of EBIT Margin shows it stood at 7.55% in 2022, then tumbled by 117 bps to 1.27% in 2023, then soared by 734 bps to 8.07% in 2024, then soared by 56 bps to 12.61% in 2025, then tumbled by 1567 bps to 185.05% in 2026.
• The last three EBIT Margin figures came in at 185.05% (Q1 2026), 12.61% (Q4 2025), and 13.74% (Q3 2025), per Business Quant data.